Skip to main content
SMFM 2025 Pregnancy Meeting Main banner
Final Program


Program Book
Icon Legend
Presentation Icons
Additional registration fee required
Additional registration fee required
CME Credit Offered
CME Credit Offered
Abstract Award
Abstract Award
Poster Icons
Additional registration fee required
Additional registration fee required
Faculty have requested this content not be shared on social media
Faculty have requested this content not be shared on social media
CME Credit Offered
CME Credit Offered
Abstract Award
Abstract Award
Back

Late-Breaking Abstract Presentations

Late-Breaking Abstract Presentations Session 2

(LB04) Neonatal impact of prematurity risk biomarker screening with targeted interventions: A multicenter randomized controlled trial

Friday, January 31, 2025
10:15 AM – 10:30 AM  
Location: Aurora Ballroom, Lobby Level
Objective: Obstetric advances have had limited impact on preterm birth (PTB) rates and neonatal outcomes. We assessed outcomes in a cohort of average risk singleton pregnancies using biomarker-based PTB risk stratification, followed by interventions for those identified at higher risk. 

Study Design: This randomized controlled trial enrolled 5,018 singleton pregnancies at 19 U.S. centers from 2020-2023. Individuals with prior PTB, short cervix, severe maternal conditions, or known genetic/fetal anomalies were excluded. We measured the ratio of maternal circulating insulin-like growth factor-binding protein 4 to sex hormone-binding globulin between 18w0d and 20w6d, with participants randomized 1:1. The control arm, blinded to test results, received usual care, while the prevention arm received test results. Prevention arm participants identified as high-risk were offered a regimen of daily vaginal progesterone, low-dose aspirin, and weekly nursing calls. Lower-risk participants in the prevention arm received usual care. Follow-up continued through delivery and neonatal discharge. The prespecified modified intent-to-treat (mITT) analysis included the control group, prevention arm low-risk participants, and high-risk participants who consented to intervention by 24 weeks, while excluding those hospitalized with COVID-19. Primary outcomes included neonatal length of stay (NNLOS) and a composite morbidity index (NMI). A planned intent-to-treat (ITT) analysis assessed multiple neonatal outcomes.

Results: Baseline characteristics did not differ between arms. mITT analysis of co-primary outcomes (Table 1) showed significantly decreased NMI and NNLOS in the prevention arm. The ITT analysis displayed significant reductions in NMI (20%), NNLOS (8%), neonatal intensive care unit (NICU) length of stay (6%), and NICU admission (20%) (Table 2). 

Conclusion: In an average risk singleton population, a mid-trimester blood test identified pregnancies at higher PTB risk, and implementing the treatment bundle significantly reduced neonatal morbidity and hospital stay compared to usual care.